Literature DB >> 12541921

[Determination of furazolidone, carbenoxolone sodium and berberine hydrochloride in wei kang tablets by reversed-phase high performance liquid chromatography(RP-HPLC)].

Ying Zhang1.   

Abstract

An HPLC method with gradient elution was developed to separate and determine furazolidone, carbenoxolone sodium and berberine hydrochloride in Wei Kang Tablets on Nova-Pak C18 column (150 mm x 3.9 mm i.d., 4 microns), using acetonitrile-phosphate buffer solution (pH 7.0) as mobile phase and 3,5-dinitrobenzoic acid as the internal standard. Detection was performed with UV detector at 254 nm. The calibration curves were linear within the ranges of 141.2 mg/L -1,270.8 mg/L for furazolidone(r = 0.9997), 100.6 mg/L -905.4 mg/L for carbenoxolone sodium(r = 0.9995) and 99.2 mg/L -892.8 mg/L for berberine hydrochloride(r = 0.9991). The recoveries and RSDs were 99.5% and 1.38% for furazolidone, 100.3% and 1.73% for carbenoxolone sodium, 97.3% and 1.97% for berberine hydrochloride respectively. The results show that this method is simple, rapid, specific, accurate and reproducible.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12541921

Source DB:  PubMed          Journal:  Se Pu        ISSN: 1000-8713


  3 in total

1.  Protective effects of carbenoxolone are associated with attenuation of oxidative stress in ischemic brain injury.

Authors:  Lang Zhang; Yu-Min Li; Yu-Hong Jing; Shao-Yu Wang; Yan-Feng Song; Jie Yin
Journal:  Neurosci Bull       Date:  2013-05-07       Impact factor: 5.203

2.  Analysis of carbenoxolone by ultra-high-performance liquid chromatography tandem mass spectrometry in mouse brain and blood after systemic administration.

Authors:  Justin L Poklis; Maciej M Gonek; Carl E Wolf; Hamid I Akbarali; William L Dewey
Journal:  Biomed Chromatogr       Date:  2019-01-07       Impact factor: 1.902

3.  Carbenoxolone does not cross the blood brain barrier: an HPLC study.

Authors:  Yevgen Leshchenko; Sergei Likhodii; Wendy Yue; William M Burnham; Jose L Perez Velazquez
Journal:  BMC Neurosci       Date:  2006-01-11       Impact factor: 3.288

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.